{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Busulfan+Test+dose&page=2", "query": { "intervention": "Busulfan Test dose", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Busulfan+Test+dose&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-20T20:53:45.272Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01237951", "title": "High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloma" ], "interventions": [ { "name": "Palifermin", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Stem Cell Transplant", "type": "PROCEDURE" }, { "name": "G-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 75, "start_date": "2010-11-08", "completion_date": "2017-09-20", "has_results": true, "last_update_posted_date": "2020-05-05", "last_synced_at": "2026-09-20T20:53:45.272Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01237951" }, { "nct_id": "NCT00469014", "title": "Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Myelodysplastic Syndrome", "Chronic Myeloid Leukemia" ], "interventions": [ { "name": "Clofarabine", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Stem Cell Infusion", "type": "OTHER" }, { "name": "Thymoglobulin (ATG)", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "60 Years", "sex": "ALL", "summary": "Up to 60 Years" }, "enrollment_count": 72, "start_date": "2006-09", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2021-01-26", "last_synced_at": "2026-09-20T20:53:45.272Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00469014" }, { "nct_id": "NCT01413178", "title": "A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myeloma" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Questionnaire", "type": "OTHER" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "High Dose Melphalan", "type": "DRUG" }, { "name": "Stem cell transplant", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 205, "start_date": "2011-09-30", "completion_date": "2019-03-10", "has_results": true, "last_update_posted_date": "2020-04-21", "last_synced_at": "2026-09-20T20:53:45.272Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01413178" }, { "nct_id": "NCT00857389", "title": "Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stem Cell Transplantation", "Leukemia", "Lymphoma" ], "interventions": [ { "name": "Thiotepa", "type": "DRUG" }, { "name": "Clofarabine", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Allogeneic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Thymoglobulin (ATG)", "type": "DRUG" }, { "name": "G-CSF (Filgrastim)", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "60 Years", "sex": "ALL", "summary": "Up to 60 Years" }, "enrollment_count": 60, "start_date": "2009-03-02", "completion_date": "2019-03-09", "has_results": true, "last_update_posted_date": "2020-04-07", "last_synced_at": "2026-09-20T20:53:45.272Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00857389" }, { "nct_id": "NCT00948090", "title": "PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 207, "start_date": "2010-01", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2014-07-31", "last_synced_at": "2026-09-20T20:53:45.272Z", "location_count": 37, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Berkeley, California + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00948090" }, { "nct_id": "NCT02766465", "title": "Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "r-ATG", "type": "DRUG" }, { "name": "Hematopoietic Cell Transplant", "type": "PROCEDURE" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Standard of Care", "type": "PROCEDURE" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Total Body Irradiation (TBI)", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "15 Years to 40 Years" }, "enrollment_count": 138, "start_date": "2017-03-16", "completion_date": "2023-08-02", "has_results": true, "last_update_posted_date": "2025-04-18", "last_synced_at": "2026-09-20T20:53:45.272Z", "location_count": 35, "location_summary": "Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 25 more", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02766465" }, { "nct_id": "NCT02589145", "title": "Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Caphosol", "type": "DRUG" }, { "name": "Glutamine", "type": "DRUG" }, { "name": "Pyridoxine", "type": "DRUG" }, { "name": "Enoxaparin", "type": "DRUG" }, { "name": "Stem Cell Transplant", "type": "PROCEDURE" }, { "name": "Palifermin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "15 Years to 65 Years" }, "enrollment_count": 8, "start_date": "2016-06-22", "completion_date": "2019-04-08", "has_results": true, "last_update_posted_date": "2019-12-13", "last_synced_at": "2026-09-20T20:53:45.272Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02589145" }, { "nct_id": "NCT03096782", "title": "Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Acute Biphenotypic Leukemia", "Acute Leukemia", "Acute Lymphoblastic Leukemia", "Acute Lymphoblastic Leukemia in Remission", "Acute Myeloid Leukemia", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Chemotherapy-Related Leukemia", "Chronic Lymphocytic Leukemia", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Chronic Myelomonocytic Leukemia", "Hodgkin Lymphoma", "Langerhans Cell Histiocytosis", "Minimal Residual Disease", "Myelodysplastic Syndrome", "Myelodysplastic Syndrome With Excess Blasts", "Non-Hodgkin Lymphoma", "Recurrent Hodgkin Lymphoma", "Refractory Acute Lymphoblastic Leukemia", "Refractory Myelodysplastic Syndrome", "Small Lymphocytic Lymphoma", "Therapy-Related Myelodysplastic Syndrome" ], "interventions": [ { "name": "Anti-Thymocyte Globulin", "type": "BIOLOGICAL" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Clofarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Filgrastim-sndz", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Umbilical Cord Blood Transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "12 Years to 65 Years" }, "enrollment_count": 6, "start_date": "2017-10-13", "completion_date": "2022-09-20", "has_results": true, "last_update_posted_date": "2023-10-11", "last_synced_at": "2026-09-20T20:53:45.272Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03096782" }, { "nct_id": "NCT02441803", "title": "Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Clofarabine", "type": "DRUG" }, { "name": "Total Body Irradiation (TBI)", "type": "RADIATION" }, { "name": "Thymoglobulin", "type": "DRUG" }, { "name": "Stem Cell Infusion", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 11, "start_date": "2015-09-14", "completion_date": "2021-09-22", "has_results": true, "last_update_posted_date": "2024-02-22", "last_synced_at": "2026-09-20T20:53:45.272Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02441803" }, { "nct_id": "NCT05327023", "title": "Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematologic Neoplasms" ], "interventions": [ { "name": "donor lymphocyte infusion", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "12 Years to 120 Years" }, "enrollment_count": 430, "start_date": "2022-05-23", "completion_date": "2029-07-02", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-09-20T20:53:45.272Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05327023" } ] }